GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer

Carlo Milandri, Rolando Polico, Domenico Garcea, Alessando Passardi, Andrea Gardini, Antonino Romeo, Emanuela Scarpi, Paola Rosetti, Laura Ridolfi, Giuliano La Barba, Marianna Ricci, Dino Amadori

Research output: Contribution to journalArticlepeer-review


Background/Aims: The aim of this prospective phase II study was to evaluate the effect of neoadjuvant GEMOX plus helical tomotherapy on the resectability of locally advanced pancreatic cancer. Methodology: Between November 2004 and July 2008, 33 enrolled patients received gemcitabine (GEM) 1000mg/m2 on day 1, and oxaliplatin (OX) 100mg/m2 on day 2, every two weeks for 3-4 cycles. This was followed by radiotherapy (25Gy, 5 fractions), 15 days after completion of GEMOX. Patients then received a further 3-4 cycles of GEMOX, underwent restaging and were evaluated for surgery. Potentially resectable patients were submitted to surgery, while unresectable responders received further GEMOX and radiotherapy. Results: Toxicity to GEMOX was similar to that reported elsewhere and radiotherapy was also well tolerated. After treatment, one patient achieved a complete response, 14 had a partial response, 11 showed a stable disease, 6 progressed, and one was not evaluable. Eight patients (24%) underwent surgical laparotomy (7 radical pancreatic resections and one explorative laparotomy). Conclusions: Our study shows the feasibility and potential efficacy of the GEMOX plus helical tomotherapy regimen in unresectable locally advanced pancreatic cancer.

Original languageEnglish
Pages (from-to)599-603
Number of pages5
Issue number106
Publication statusPublished - Mar 2011


  • Locally advanced pancreatic cancer
  • Neoadjuvant therapy
  • Radiotherapy

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'GEMOX plus tomotherapy for unresectable locally advanced pancreatic cancer'. Together they form a unique fingerprint.

Cite this